Howland Capital Management LLC reduced its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,292 shares of the biopharmaceutical company’s stock after selling 30 shares during the quarter. Howland Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $2,357,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of BMY. Ameriprise Financial Inc. grew its stake in shares of Bristol-Myers Squibb by 18.7% during the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares in the last quarter. Swiss National Bank grew its stake in shares of Bristol-Myers Squibb by 27.2% during the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares in the last quarter. State Street Corp grew its stake in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares in the last quarter. NN Investment Partners Holdings N.V. grew its stake in shares of Bristol-Myers Squibb by 103.1% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 1,581,454 shares of the biopharmaceutical company’s stock worth $88,119,000 after acquiring an additional 802,931 shares in the last quarter. Finally, Karp Capital Management Corp bought a new position in shares of Bristol-Myers Squibb during the 1st quarter worth approximately $38,890,000. 68.80% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/16/howland-capital-management-llc-decreases-stake-in-bristol-myers-squibb-company-bmy.html.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II purchased 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.33% during midday trading on Friday, reaching $62.48. The company’s stock had a trading volume of 10,407,558 shares. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.47. The firm has a 50-day moving average of $58.56 and a 200-day moving average of $55.95. The stock has a market cap of $102.46 billion, a PE ratio of 22.82 and a beta of 1.18. Bristol-Myers Squibb also was the target of unusually large options trading on Thursday. Investors purchased 781 put options on the stock. This represents an increase of approximately 117% compared to the average daily volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the prior year, the company posted $0.69 earnings per share. Bristol-Myers Squibb’s revenue was up 5.6% compared to the same quarter last year. On average, analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.50%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.
Several equities analysts have recently weighed in on the stock. Hilliard Lyons cut shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target for the company. in a research note on Tuesday. Jefferies Group LLC raised their price target on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Credit Suisse Group reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a research note on Friday, September 8th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 price target for the company. in a research note on Thursday, September 7th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $65.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $62.66.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.